The San Francisco-based drugmaker said in a letter June 23 that the patients died after experiencing liver problems that appeared to be linked to its experimental drug.
X-linked myotubular myopathy is a condition that causes severe muscle weakness, and most patients with the disorder don’t survive childhood.
Audentes CEO Natalie Holles told STAT that the company has stopped enrolling new patients in the study, and shortly after the company’s decision, the FDA placed a clinical hold on the study.
Ms. Holles said that the company will investigate the two deaths thoroughly.
“While this is a terrible loss and it’s heartbreaking, we see a path forward here, and we’re redoubling our efforts as a company to get products to patients as quickly as possible and as broadly as possible, recognizing that we have to do that safely,” Ms. Holles told STAT.
Read the full report here.
More articles on pharmacy:
Cheap steroid in shortage after being posited as potential COVID-19 treatment
Regeneron paid patient charity millions in kickbacks, lawsuit claims
Novartis pays DOJ, SEC $347M in kickback scheme settlement
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.